Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.68 |
| ▸ | HPGD | P15428 | 8/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.67 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | PDE2A | O00408 | 1/20 | 0.52 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17732302 | 0.87 | KDM4E (0.66) | KDM4EHPGDALDH1A1HSD17B10NPC1 | |
| SCHEMBL17732305 | 0.87 | KDM4E (0.56) | KDM4EHPGDALDH1A1HSD17B10NPC1 | |
| SCHEMBL17732301 | 0.86 | KDM4E (0.65) | KDM4EHPGDALDH1A1HSD17B10NPC1 | |
| SCHEMBL10407266 | 0.86 | KDM4E (0.55) | KDM4EHPGDALDH1A1HSD17B10NPC1 | |
| SCHEMBL9300300 | 0.86 | KDM4E (0.55) | KDM4EHPGDALDH1A1HSD17B10NPC1 | |
| SCHEMBL14124198 | 0.85 | KDM4E (0.63) | KDM4EHPGDALDH1A1HSD17B10NPC1 | |
| SCHEMBL14124251 | 0.85 | KDM4E (0.57) | KDM4EHPGDALDH1A1HSD17B10NPC1 | |
| SCHEMBL18208794 | 0.84 | KDM4E (0.56) | KDM4EHPGDALDH1A1HSD17B10NPC1 | |
| SCHEMBL21948230 | 0.84 | KDM4E (0.53) | KDM4EHPGDALDH1A1HSD17B10NPC1 | |
| SCHEMBL4262729 | 0.84 | KDM4E (0.53) | KDM4EHPGDALDH1A1HSD17B10NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340558-A1 | CRYSTALLINE SUBSTITUTED CYCLOHEXYL PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUND AND THERAPEUTIC USES THEREOF | BIAL R&D INVEST S A (PT) | 2025-11-06 | — | — | US | disclosed |
| US-20250066364-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2025-02-27 | — | — | US | disclosed |
| EP-4406616-A2 | SUBSTITUTED PYRAZOLO(1,5-A)PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Bial-R&D Investments, S.A. (PT) | 2024-07-31 | — | — | EP | disclosed |
| EP-3215511-B1 | SUBSTITUTED PYRAZOLO(1,5-A)PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2024-04-17 | — | — | EP | disclosed |
| US-11932645-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | Bial—R & D Investments, S.A. (PT) | 2024-03-19 | — | — | US | disclosed |
| US-20220169652-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. | 2022-06-02 | — | — | US | disclosed |
| US-20220169652-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. | 2022-06-02 | — | — | US | disclosed |
| EP-3366688-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | US HEALTH (US) | 2022-02-09 | — | — | EP | disclosed |
| US-11091492-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2021-08-17 | — | — | US | disclosed |
| US-11091492-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2021-08-17 | — | — | US | disclosed |
| WO-2016073895-A1 | SUBSTITUTED PYRAZOLO(1,5-A)PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016073895-A1 | SUBSTITUTED PYRAZOLO(1,5-A)PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| US-20140249145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2649075-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012078855-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-06-14 | — | — | WO | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20090182142-A1 | Aromatic Compound | FURUKUBO SHIGERU | 2009-07-16 | — | — | US | disclosed |
| US-4908056-A | Herbicides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-13 | — | — | US | disclosed |
| US-4838925-A | HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-06-13 | — | — | US | disclosed |
| EP-0244166-A2 | Heterocyclic acetyl sulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932645-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | PARK7, PNP, GAA | KDM4E 899/4885HPGD 1396/4885ALDH1A1 1213/4885 |
| US-20250340558-A1 | CRYSTALLINE SUBSTITUTED CYCLOHEXYL PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUND AND THERAPEUTIC USES THEREOF | GBA1, GAA, PARK7 | KDM4E 1033/4885HPGD 2660/4885ALDH1A1 3776/4885 |
| US-20140249145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | GBA1, GAA, GBA3 | KDM4E 2174/4885HPGD 2444/4885ALDH1A1 2433/4885 |
| US-20220169652-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PARK7, PNP, GAA | KDM4E 899/4885HPGD 1396/4885ALDH1A1 1213/4885 |
| US-20090182142-A1 | Aromatic Compound | HRH4, CCR4, HRH3 | KDM4E 1026/4885HPGD 2189/4885ALDH1A1 1906/4885 |
| US-20250066364-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PARK7, PNP, GAA | KDM4E 899/4885HPGD 1396/4885ALDH1A1 1213/4885 |
| US-11091492-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | PARK7, PNP, GAA | KDM4E 899/4885HPGD 1396/4885ALDH1A1 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.